Efficacy and Safety of Weekly Low Dose Paclitaxel and Cisplatin as First Line Therapy in Advanced NSCLC of Elderly Patients

摘要: Purpose: Anti-cancer chemotherapeutic agents act by inhibiting tumor cell proliferation through cytotoxic action, therefore the generally tolerated maximum dose is administered to patients. However, this often results in production of undesirable toxicities, such as bone marrow suppression, and a long interruption treatment necessary for recovery occur before additional cycles are administered. Paclitaxel cisplatin well known effective used Non-Small Cell Lung Cancer (NCSLC), however, they have substantial toxicities. To evaluate efficacy safety therapy consisting weekly low paclitaxel elderly patients with advanced NSCLC. Materials Methods: Thirteen treatment-naive, over 65 years old who were diagnosed stage IV NSCLC at Konyang University from April 2005 October 2006 enrolled present study. 55 mg/m2 combination 20 mg/m 2 was intravenously on day 1, 8, 15 1 week total six chemotherapy. Results: The mean age ten included study 69.5 years. Following treatment, 50 % exhibited partial response whereas disease remained stable 40% patients, progressed 10% median survival time (Kaplan-Meier method) months (4 ∼24 months), 6-month, 1-year, 2-year rates 80%, 50%, 10%, respectively. progression 8 (2 ∼14 months) 6- 12-month free 60% Grade 3 neutropenia occurred only case (10%). Conclusion: indicated that chemotherapy could be more lesser toxicity when In addition, regimen showed promising rate. (J 2007;6(2):85�� 90)